top of page

Exploring Weight Loss Injections: Wegovy, Ozempic, and Saxenda

Weight loss injections have gained significant popularity as a potentially more convenient method for reducing excess weight. These injections replicate a hormone that enhances feelings of fullness and suppresses appetite. However, it is important to recognize that weight loss injections should not be regarded as a quick fix and should be used alongside a healthy diet and regular exercise.


It is worth noting that weight loss injections are recommended for individuals classified as obese or those classified as overweight with at least one weight-related comorbidity. In this article, we will delve into the most popular weight loss injections available: Wegovy, Ozempic, and Saxenda.



Effectiveness of Wegovy for Weight Loss


Wegovy has been scientifically proven to be highly effective in reducing body weight. The dosage and effectiveness of Wegovy may vary depending on the individual. Clinical trials have demonstrated that the maximum dosage (2.4mg) of Wegovy enables individuals to lose 12% more body weight compared to those using a placebo for weight loss. In a 68-week trial conducted by Novo Nordisk, the manufacturer of Wegovy, patients who received Wegovy experienced a remarkable 14.9% reduction in body weight, whereas those given a placebo only saw a 2.4% decrease. It is crucial to remember that Wegovy is a prescription-only medication and should be taken weekly in conjunction with a healthy diet and regular exercise.




Differentiating Wegovy from Ozempic


While both Wegovy and Ozempic contain the active ingredient Semaglutide, they differ in their primary purposes. Wegovy is intended for chronic weight management, whereas Ozempic is primarily prescribed to treat type 2 diabetes by regulating blood glucose levels. Nonetheless, Ozempic has also shown weight loss benefits due to its appetite-suppressing effects. This is why Ozempic is being prescribed off-label to individuals who wish to lose weight and do not have type 2 diabetes. Additionally, Wegovy is available in higher dosages compared to Ozempic, and clinical trials have demonstrated that the maximum dosage of Wegovy leads to significantly greater weight loss in patients.


Comparing Wegovy and Saxenda


Wegovy has been proven to be more effective in reducing weight than Saxenda. In a randomized controlled trial, Wegovy demonstrated a substantial 15.8% reduction in body weight, while Saxenda resulted in only a 6.4% decrease. However, in a separate clinical study spanning 56 weeks, three out of five individuals taking Saxenda lost an average of 5kg, and one out of three lost an average of 10kg. Although Saxenda may not be as effective as Wegovy, it can still be a viable option for weight loss. It is worth noting that Saxenda caused 50% more individuals to discontinue the treatment due to side effects compared to Wegovy. Overall, Wegovy appears to be a more effective and better-tolerated weight loss treatment than Saxenda. However, individual responses may vary, and some individuals may find Saxenda to be more suitable for their needs.


In conclusion, determining the most suitable weight loss injection depends on individual factors. Clinical studies have demonstrated Wegovy's effectiveness in weight loss, but considering personal circumstances is crucial when selecting the right injection. Consultation with a healthcare professional is essential to determine which treatment option is best for you


If you are taking a weight loss injection and looking for dietary support and guidance, it is advisable to seek assistance from a qualified nutrition professional. Collaborating with an expert will enable you to develop a sustainable and efficient approach to achieving your weight loss objectives.


Book a free discovery call today to find out more information on Nutrition and Co's services



Reference list:


Davies, M. et al. (2021) Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial, The Lancet, 397 (10278) pp.971–984.


Twenefour, D. (2023) Wegovy: The key facts to know about the weight loss drug. Available at: https://www.diabetes.org.uk/about_us/news/wegovy-key-facts-know-about-weight-loss-drug#:~:text=Wegovy%20can%20lead%20to%20weight (accessed 26 May 2023).





42 views0 comments

Comentários


bottom of page